Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study Between 2018 and 2020, overall 91 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results